Novel Therapeutic Options for Small Cell Lung Cancer.
Stefania CanovaBenedetta TrevisanMaria Ida AbbateFrancesca ColoneseLuca SalaAlice BaggiSofia Paola BianchiAnna D'AgostinoDiego Luigi CortinovisPublished in: Current oncology reports (2023)
In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies.